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Background: Long chain polyunsaturated fatty acids (LCPUFAs) have been shown to reduce 
blood pressure (BP) while they are being consumed; however, there is also evidence from 
observational studies that exposure to more LCPUFA early in development can program lower 
BP in childhood. This relationship has yet to be studied in a randomized trial conducted during 
fetal life. 
Objective: We tested the hypothesis that 600 mg/d of the omega-3 LCPUFA docosahexaenoic 
acid (DHA) compared to placebo in pregnancy can reduce offspring BP at 7 and 8 years of age. 
Methods: This secondary data analysis examines 129 offspring from women who consumed 
capsules (placebo or 600 mg DHA) from <20 weeks of gestation to birth. BP was measured in 
triplicate at 7 and 8 years of age. The statistical analysis was intent-to-treat with adjustment for 
covariates associated with BP. 
Results: We did not find an effect of early DHA exposure on BP, however, child weight status 
(BMI percentile < or ≥85
th 
percentile) and gestational days smoked were positively associated 
with BP at 7 and 8 years of age. 
Conclusion: Improving maternal and therefore fetal DHA status through maternal DHA 
supplementation during pregnancy does not appear to protect against higher BP at 7 and 8 years 
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Chapter 1: Introduction 
Long chain polyunsaturated fatty acids (LCPUFAs) have been shown to reduce blood 
pressure (BP) in adults (1).There is also some evidence from a randomized trial that exposure to 
LCPUFA during the first 4 months of life can program lower BP in childhood (2) however, the 
effect of fetal LCPUFA exposure on child BP has not been studied in a randomized trial. A 
randomized trial in Denmark looked at the effect of supplementation of docosahexaenoic acid 
(DHA) during the first 4 months of lactation and found higher BP in boys but not in girls at 7 
years (3) and 13 years (4). Two more studies in Denmark studied dietary DHA intake at 8-11 
years and 17 years and found higher amounts of DHA were associated with higher BP in 
children at 8-11 years (5)  and 17 years (6). 
In contrast, Vidakovic et al. (7) associated maternal DHA status in pregnancy with lower 
childhood BP at 6 years, and Forsyth et al. (2) found lower BP in children at 6 years who were 
provided a formula with DHA and arachidonic acid for the first 4 months of infancy.  Studies by 
Ryter et al. (8), De Jong  et al. (9), and Ayer et al. (10) found no relationship between DHA 
supplementation during the second trimester, the first 2 months of life, or over the first 5 years of 
life, respectively, and BP at 20 years, 9 years, and 8 years. Although multiple studies have been 
conducted on DHA and childhood BP, a consensus has yet to be reached. 
No study to date has followed BP in children whose mothers were randomly assigned to 
DHA supplementation during pregnancy, thus exposing them to different amounts of DHA in the 
fetal environment. However, early reports from our own cohort suggest lower BP from 4 to 6 
years in overweight/obese children whose mothers received 600 mg/d of DHA for the second 
half of pregnancy compared to overweight/obese children whose mothers received a placebo 
(under review). This and some of the observational studies suggest that there are long-term 
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programming effects of improving DHA exposure early in development. To examine, perhaps 
even longer term effects, we chose to measure BP in the children who had been studied from 4 to 
6 years when they were 7 and 8 years of age. 
 
Research Questions 
Primary:  Does supplementing with 600 mg/d DHA compared to a placebo during pregnancy 
result in lower BP at 7 and 8 years of age among the offspring? 





Chapter 2: Review of Literature 
Introduction 
 Heart disease is the number one cause of death worldwide (11). High blood pressure (BP) 
is a contributing factor to heart disease, and while it currently affects adults at a greater rate than 
children, hypertension rates in children are rising (12). Additionally, hypertension tracks from 
childhood into adulthood which is why early screening and intervention is important (12). While 
identifying and treating hypertension is important, finding ways to avoid hypertension altogether 
is a vital research mission in of itself.  
 Long chain polyunsaturated fatty acids (LCPUFAs) have been shown to decrease BP in 
adults (5), and researchers have begun to investigate whether the same BP-lowering effects 
present in adults are found in children. Data are mixed on the outcomes of early life postnatal 
DHA supplementation (2-4, 9, 10, 13). One observational study suggests prenatal exposure is 
related to lower BP in childhood (7), however, none of the current studies have examined 
random assignment to DHA exposure in developing fetuses and child BP.  We have found lower 
SBP and DBP in children between 4 and 6 years of age who became overweight/obese if their 
mothers received DHA during pregnancy compared to overweight/obese children whose mothers 
received a placebo  (14).  
 In summary, current research is inconclusive, and more randomized controlled trials 
conducted during fetal life are needed to show the effect of intrauterine LCPUFA exposure on 
childhood BP. We found an effect of early DHA exposure on later childhood BP when children 
were 4 to 6 years of age. The purpose of this study was to examine if supplementation with 
LCPUFAs continues to show a relationship to childhood BP in these same children when they 




High blood pressure prevalence in children 
National hypertension prevalence in children is about 3.5% (15). However, the rate is 
likely higher because hypertension is underdiagnosed in this population (16). According to 
Muntner et al, BP levels in children have increased in the past decade and mirror increases in 
obesity rates (17). When only looking at data of obese adolescents, the combined hypertension 
and pre-hypertension rates are about 30% (18). Although obese individuals are more susceptible 
to hypertension, children of all sizes can be affected, which is why screening is so important.  
Hypertension diagnosis in children 
Current recommendation is to check BP starting at age three (18). Early screening allows 
physicians to predict susceptibility to hypertension in the future (18). Diagnosis is based on set 
BP tables that have percentiles based on height, sex, and age for children ages 1 through 17 (18). 
BP ranges for children 1-13 years is shown in Table 1. Diagnosis of hypertension should be 
made after the confirmation of BP ≥95
th





Table 1. Blood pressure ranges for children 1-13 years 
Normal blood pressure <90%ile 
Elevated blood pressure ≥90%ile to <95%ile or 120/80 to <95%ile  
(whichever is lower) 
Stage 1 hypertension ≥95%ile to <95%ile, plus 12mm Hg, or 130/80 to 139/89 
(whichever is lower) 
Stage 2 hypertension ≥95%ile , plus 12mm Hg, or  ≥140/90mm Hg  
(whichever is lower) 
 
Primary and secondary hypertension 
Primary hypertension does not have a known origin, while secondary hypertension is 
caused by an underlying disease (16).  Common causes of secondary hypertension include renal 
disease, heart disease, endocrine disease, family history, low birth weight, and being overweight 
(16). Other cardiovascular risk factors such as insulin resistance and dyslipidemia are often seen 
in adolescents with hypertension (20).  
Health implications of high blood pressure in adults 
While there are many causes of hypertension, it is important to get BP levels within 
healthy ranges to avoid negative health consequences. Although heart disease is thought to 
mainly affect adults, it could begin as early as infancy with hypertension and follow into 
adulthood, triggering many other problems (12). Coronary heart disease, stroke, and chronic 
kidney disease can all be associated with hypertension (21).  Polyunsaturated fatty acids 
(PUFAs) could play a role in childhood hypertension. 
 
Polyunsaturated fatty acid background 
Essential fatty acids 
 Essential fatty acids are those that are essential to body function, but cannot be 
synthesized by the body, and therefore must be consumed from a food source or supplement 
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(22). The essential fatty acids include the omega-6 fatty acid, linoleic acid (LA), and its 
derivative arachidonic acid, and the omega-3 fatty acid, alpha-linolenic acid (ALA), and its 
derivatives eicosapentaenoic acid (EPA) and DHA (22). LCPUFAs that have been associated 
with BP are EPA and DHA.  
LCPUFAs and dietary sources 
While EPA and DHA can be converted from the shorter chained PUFA, ALA, this 
process is inefficient, meaning our bodies need to acquire direct sources of EPA and DHA (23). 
ALA is found in many food sources such as vegetable oils and walnuts; EPA and DHA are 
mainly found in fatty fish like salmon, tuna, mackerel, anchovy, and sardines (24). DHA is also 
an important component of human milk, but the levels vary based on genetics and maternal 
intake (25). As infant formulas try to simulate human milk as closely as possible, LCPUFAs are 
frequently added to formula (9).  
LCPUFAs role in fetal and infant development 
LCPUFAs are essential nutrients during fetal and infant development. EPA and DHA are 
especially important in fetal brain and retina development (26). DHA is considered more 
important than EPA as it is found in high concentrations in neural membranes and plays a major 
role in the function of the cell membranes (26). In contrast, EPA and EPA metabolites have 
many functions, but they are not found in high concentrations in cell membranes. Maternal 
intake of these essential fatty acids is directly related to the amount found in the fetus or infant 
(23). According to the U.S. Department of Health and Human Services, pregnant and 
breastfeeding mothers should consume 8-12 ounces of fish per week (23). If this guideline 
cannot be met, it is recommended to consume a daily supplement containing a minimum of 2.6 g 
omega-3 fatty acids with 100-300 mg of that being DHA (22).  
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LCPUFA role in blood pressure 
 In addition to playing a role in fetal and infant development, these LCPUFAs are thought 
to impact BP as well. LCPUFAs have been shown to lower BP in adults, but the effect in 
children is uncertain (5). LCPUFAs act as a hypotensive agent in adults by controlling sodium 
and water excretion, inhibiting the vasoconstrictor actions of thromboxane, interfering with 
vasopressor hormone responses, and acting as an anti-inflammatory agent (7). While these 
mechanisms of action are seen in adults, responses to LCPUFAs in children are less studied. In 
addition, there is the suggestion that early DHA exposure may program lower BP in early 
childhood and possibly even longer through some effect on early development that is not yet 
known.  
 
Evidence that fish oil increases blood pressure 
In the Danish study conducted by Asserhoj et al.(3) and Lauritzen et al. (2016) (4), 
participants were assigned to either a fish oil supplement group (containing 1.5g/d LCPUFAs) or 
an olive oil group for the first 4 months of lactation. Asserhoj et al. (3) examined 98 children 
while Lauritzen et al. (2016) (4) examined 103 Danish children. In the other Danish studies 
conducted by Damsgaard et al. (5) and Lauritzen et al. (2012) (6), dietary intake of the children 
was assessed by a 7-day recorded food record the week before BP was measured. The studies 
included 73 and 109 Danish children, respectively (5, 6). The children’s BP was measured at 7 
years (3), 8-11 years (5), 13 years (4), or 17 years of age (6).  
Asserhoj et al. (3) found that BP did not differ in females, while males in the fish oil 
group had 6 mm Hg higher DBP and mean BP than compared with the males in the olive oil 
group. Damsgaard et al. (5) and Lauritzen et al. (2016) (4) found similar results in that LCPUFA 
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intake was associated with high BP in males only. Lauritzen et al. (2012) (6) found these same 
results in both males and females.  
In a study analyzing 229 children living in the Netherlands, conducted by Seggers et al. 
(27), arachidonic acid and DHA levels were measured at birth from the umbilical cord. The 
children’s BP was measured later at 9 years of age. It was found that greater arachidonic acid 
levels and a greater arachidonic acid to DHA ratio was associated with a lower DBP at 9 years of 
age. This is opposite of the findings expected in adults as arachidonic acid is considered 
adipogenic (27).  
 While these studies all found similar results, they still had limitations. The Lauritzen et 
al. (2012) (6) study and the Damsgaard et al. (5) study relied on food logs in order to determine 
LCPUFA intake. This method could be flawed as amount of food eaten can be inaccurately 
recorded or may not be an accurate representation of the children’s actual intake (5, 6). Although 
blood samples were taken to analyze the fatty acid content, it is unknown how much LCPUFAs 
they were actually exposed to (5, 6). It is also unknown if supplementation during the first 4 
months of life is a long enough intervention to exhibit the desired effects or if supplementation 
needs to occur even earlier in life (3, 4).  While these studies all showed increases in BP, other 
studies have shown a decrease in BP with LCPUFA intake. 
 
Evidence that fish oil decreases blood pressure 
In the study examining 4,455 children conducted in the Netherlands (7), no LCPUFA 
supplementation was provided but the maternal LCPUFA levels were measured during the 
second trimester. In the study conducted by Forsyth et al. (2), which analyzed 235 infants from 
European centers located in Italy and United Kingdom, the infants were fed either a LCPUFAs 
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supplemented formula or an un-supplemented formula for the first 4 months of life. BP of both 
groups was measured at 6 years of age (2, 7). 
Vidakovic et al. (7) found that greater maternal omega-3 PUFA and specifically DHA 
levels were related to lower offspring SBP at age 6, while DBP remained unchanged. However, 
the differences were only -0.28 and -0.29 mm Hg per SD increase of total maternal omega-3 
PUFAs and DHA weight % respectively (7).  Another study from the same cohort analyzed the 
data using a principal component analysis model which allowed them to better analyze the 
patterns of fatty acids present in the mothers during pregnancy and they did not find an effect of 
maternal plasma fatty acid patterns on childhood BP (13).  
Breastfeeding appeared to have a beneficial relationship with offspring BP. The breastfed 
control children had similar BP levels to children born to mothers with greater omega-3 levels 
(7). Vidakovic et al. (7) also observed that a greater omega-6 to omega-3 ratio was related to a 
greater SBP. Forsyth et al. (2) found similar results in which the LCPUFAs supplemented infants 
had a lower mean and DBP at 6 years of age. The researchers examined the design and 
discovered the following possible study limitations. 
Vidakovic et al. (7) examined maternal LCPUFA status during the second trimester. This 
may not be an accurate representation of fetal LCPUFA status, as this can vary based on the 
amount that is actually transferred to the fetus (7). While the infants in the Forsyth et al. study 
received supplemented formula for the first 4 months of life, the diet after this period was not 
evaluated, leaving room for the children to consume unknown amounts of LCPUFAs (2). And 
again, supplementing during the first 4 months of life may not be a long enough or early enough 




Evidence that fish oil has no relationship with blood pressure 
In the study conducted by Ayer et al. (10), 616 Australian families were supplied with 
canola-based oils and spreads to use in cooking and eating. They were also instructed to give 
their child a daily tuna oil capsule (135mg DHA/capsule). The control groups were given sunola 
oil to use in their diet (10). These diet interventions were implemented from the time they started 
eating solids until 5 years of age (10). The study conducted by Ryter et al. (8) measured maternal 
LCPUFAs levels from 443 Danish mothers during the second trimester. The study conducted in 
the Netherlands by Pluymen et al. (28) compared BP at 5 years of age of 2,468 newborns fed 
infant formula supplemented with LCPUFA and those who consumed formula without 
LCPUFAs.  In the final study conducted by De Jong et al. (9), 474 infants from  the Netherlands 
received formula supplemented with LCPUFAs (0.35% by wt DHA) from birth until 2 months of 
age. These children were compared to infants given standard formula and those who were 
breastfed (9). 
The children’s BP was measured at 8 years (10), 20 years (8), 5 years (28) and 9 years 
(9). In all of these studies, no differences were found between those who had greater LCPUFA 
intake during pregnancy (8), infancy (9, 28), or early childhood (10) when compared to those 
who had less.  
The researchers examined the design and discovered the following possible study 
limitations. Ayer et al. (10) suggested a reason for the findings was an insufficient amount of 
LCPUFAs. While the canola-based and tuna oils positively altered the omega-3 to omega-6 ratio, 
the omega-3 levels remained below those found in areas where fish intake is high (10). De Jong 
et al. (9) noted that the short supplementation period of 2 months could be a limiting factor as 




As multiple studies have resulted in various conclusions, the answer still remains as to 
how LCPUFAs affect BP in children. While LCPUFAs play an important role in the 
development of infants and children, their effect on childhood BP is still unknown. Flaws in 
some of these experiments include limited supplementation time, supplementation during the 
incorrect periods of time, and an insignificant amount of LCPUFA. Also none of these studies 
were conducted in the United States. Further research on LCPUFAs and BP is needed to clarify 
the effects LCPUFAs have on adolescents’ BP. Research conducted in which DHA is 





Chapter 3: Methods 
Overview of Parent Trial 
 This study is designed to test the effect of 600 mg/d of DHA supplementation during 
pregnancy on childhood BP at 7 and 8 years of age. A total of 350 women from Kansas City 
metropolitan area between the ages of 16 and 35.99 and between 8 to 20 weeks of gestation were 
recruited from January 2006 and November 2009 to participate in a study on the effect of DHA 
supplementation on gestation duration and early infant cognition (29). After the conclusion of the 
primary and secondary studies, the women were asked to continue in a tertiary study to measure 
the children’s body composition and BPs at 7 and 8 years of age. 
 
Setting 
 The original cohort for the KU DHA Outcomes Study (KUDOS) trial was recruited from 
the Kansas City metropolitan area. They were recruited from January 2006 to November 2009. 
The study was conducted from 2006 to 2011 (29). 
 
Ethics 
 Both the research protocol and informed consent process were in compliance with the 
Declaration of Helsinki, and were approved by the Institutional Review Boards/Human Subjects 
Committee at the University of Kansas Medical Center, the University of Missouri-Kansas City; 







Three hundred fifty healthy, English-speaking pregnant women between the ages of 16 to 
35.99 and 8 to 20 weeks of gestation who planned on delivering in the Kansas City metropolitan 
area were recruited to participate. Exclusion criteria for the original trial included BMI  ≥40, 
expecting multiple infants, preexisting diabetes mellitus or SBP ≥140 mm Hg at enrollment, or 
had any serious health condition likely to affect development and growth of the offspring. These 




 After participating in the informed consent process, eligible women were randomized 
into either a corn/soy oil placebo group (0 mg DHA) or a marine algae-oil source (600 mg 
DHA). Both supplements were provided by DSM Nutritional Products, Columbia, MD. 
Regardless of group women were instructed to consume 3 capsules/day until birth. The women 
were encouraged to consume the 3 capsules/day, but if this was not possible, the women were 
told to consume as many capsules as they could up to 3 capsules/day. The participants were 
blinded to the randomization until the children were 6 years of age and had completed early 
cognitive and visual acuity development testing. The study team will remain blinded until 
completion of the study (29).  
 
Capsules 
 A month’s supply of capsules was mailed to the participants and the participants were 
asked to mail the unused capsules back to the investigational pharmacy in a prepaid envelope. 
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The pharmacy then counted and recorded the unused capsules and destroyed the remaining 
capsules. This count was used to determine capsule intake for the participants. A minor financial 
incentive was provided for mailing back the used capsules (29). 
 
Blood Analysis 
A blood sample was collected from participants at enrollment and the morning after 
delivery. Venous cord blood was obtained at the time of birth. This blood was analyzed for fatty 
acid content by way of gas chromatography. Blood samples were collected by venipuncture into 
5-mL sodium–EDTA tubes (Vacutainer; Becton-Dickinson) and placed on ice immediately. 
Plasma and red blood cells (RBCs) were separated by centrifugation (3000 3 g, 10 min; 48C), 
frozen, and stored under nitrogen at 2808C until analyzed (29). Lipids were isolated according to 
a modification of Folch et al (30), and RBC lipids were fractionated  (31) by thin-layer 
chromatography. RBC phospholipids were transmethylated with boron trifluoride- methanol 
(32), and the resulting fatty acid methyl esters were separated by using a Varian 3900 gas 
chromatograph with an SP-2560 capillary column (100 m; Sigma Aldrich) as previously reported 
(33) and a Star 6.41 Chromatography Workstation for peak integration and analysis. Injector and 
detector temperatures were programmed at 2608C. The column temperature program for the 41-




 C increase/min to 240
o
 C, and held at 240
o
 C 
for 11 min. Individual peaks were identified by comparison with qualitative standards (PUFA 1 
and PUFA 2; Sigma Aldrich), and a weighed standard mixture (Supelco 37 Component FAME 
mix; Sigma Aldrich) was used to adjust fatty acids for area/weight to calculate a final percentage 
weight of total fatty acids. RBC-phospholipid-DHA is reported as a percentage of total fatty 
acids by weight (29). 
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KUDOS Body Composition Study 
Of the 350 women enrolled in the parent KUDOS trial, 172 were assigned to the placebo 
group and 178 were assigned to DHA. At the completion of the 6 year project, a total of 166 
participants completed their visit, with 81 children remaining in the placebo group and 85 in the 
DHA group. These families were asked to continue in an ancillary study, known as the KUDOS 
Body Composition (KUDOS Body Comp) follow-up from ages 7 to 9 years old. The primary 
outcome of KUDOS Body Comp was to determine the influence of prenatal DHA on child fat 
and fat free mass during late childhood. Food intake, physical activity, body composition, height, 
weight, heart rate, and BP were measured. 
After informed consent of the parent and assent of the child, families were asked to come 
to the study site once a year near the child’s birthday for one visit which lasted about 1 hour. 
During which time the parent(s) (with the assistance of child if needed) filled out questionnaires 
regarding child exposure to foods with DHA, physical activity, and parenting styles. A 24-hour 
recall was also conducted. Six site (sub-scapular, triceps, biceps, abdominal, hip and thigh) skin 
fold measurements were measured at least in duplicate according to standard laboratory practice 
as well as child BP (process expanded below), and the BodPod body composition measurement 
according to industry standards. 
 
Blood Pressure Measurements 
SBP and DBP measurements were recorded three times by trained staff using an 
automated sphygmomanometer. BP was measured after the children had been lying down for 2-3 
minutes while their sagittal abdominal diameter was measured. The BP measurement was taken 
using an appropriate cuff size on the left arm and the cuff was kept at the level of the heart. 
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Proper cuff size was chosen by ensuring the index line on the cuff was between the indicated 
marks on the cuff. A smaller or larger cuff size was chosen if these index lines did not fall 
between the designated markers. The cuff was wrapped around the arm, with the arrow marked 
artery aligning with the patient’s brachial artery. Heart rate was also measured three times in a 
row with the same equipment as the BP. Average SBP and DBP measurements were calculated 
using the last two measures, and the coefficient of variance (CV) determined for each average. If 
the CV was ≥0.095, the two measures of the three taken that were closest were averaged instead.   
 
Materials 
 The data collected included sex, race, height, weight, heart rate, and BP of the children 
and the corresponding amount of DHA given during pregnancy, maternal pre-pregnancy body 
mass index (BMI), gestational days smoked, and days breast fed. The equipment utilized 
included a sphygmomanometer, stadiometer, and scale. Child BMI percentile was calculated 
using EZ-BMI calculator software version 2013. In accordance with standard practice, the 
software used the child’s age, sex, date of birth, date of measurement, height, and weight to 
determine the child’s BMI percentile. 
 
Statistical Analysis 
 All statistical analyses were conducted with SPSS 25 (IBM). The dependent variables for 
this study were SBP and DBP (mm Hg) at 7 and 8 years. The following potential variables were 
examined with respect to child blood pressure: breastfeeding, gestational weight gain, child and 
maternal weight status, gestational days smoked, and child race and sex. A correlation matrix 
was built using the Pearson’s correlation to identify any relationship between SBP or DBP at 7  
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and 8 years and child weight status, gestational days smoked, and pre-pregnancy weight status. 
Analysis of covariance (ANCOVA) was used to identify any effect of DHA assignment (placebo 
or 600mg DHA) for SBP and DBP at 7 and 8 years. The ANCOVA was adjusted for child 
weight status, gestational days smoked, pre-pregnancy weight status, child sex, and child race 







Chapter 4: Results 
The primary purpose of the study is to determine if DHA supplementation during 
pregnancy influences BP at 7 and 8 years of age. Our hypothesis is that DHA supplementation 
results in lower BP in childhood.  A secondary purpose of this study is to find predictors of 
increased childhood BP. Our hypothesis is that a predictor of increased childhood BP is child 
weight status. A total of 129 children participated in the cohort at 7 and 8 years. Of these, 63 
were randomly assigned to placebo and 66 to DHA (Table 2). We have BP measurements for 












Maternal pre-pregnancy weight status (%)   
       Underweight/normal weight 60 43 
       Overweight/obese 40 57 
Smoked during pregnancy (%) 37 35 
Average days smoked among those who smoked 155 144 
Breast fed (%) 87 79 
Average days breast fed among those who breastfed 226 253 
7 year child weight status (%)   
       <85
th 
percentile 80 69 
       ≥85
th
 percentile 20 31 
8 year child weight status (%)   
       <85
th 
percentile 78 71 
       ≥85
th 
percentile 22 29 
Child race (%)   
       African American 37 29 
       Not African American 63 71 
Child ethnicity (%)   
       Hispanic 6 6 
       Not Hispanic 94 94 
Child sex (%)   
       Males 54 41 
       Females 46 59 
DHA change cluster (%)   
       Increase 12 66 
       Flat 88 34 
Average change in DHA from enrollment to delivery (% red 
blood cell-phospholipid-DHA by weight) 
+0.290765 +3.274828 
Average blood pressure (Systolic/Diastolic)   
       7 year 103/62 102/62 
       8 year 104/64 104/63 
Child fish and DHA supplement intake  
(average times/week) 
  
       7 year 1.3 1.1 
       8 year 1.3 0.8 




Analysis of covariance 
Table 3 shows the ANCOVA results for 7 year SBP and DBP. There is no significant 
difference between placebo and DHA group for 7 year SBP or DBP (P = 0.625 and P = 0.431, 
respectively). Figures 1 and 2 show the means for 7 year SBP and DBP for placebo and DHA 
groups.  The means are adjusted for 7 year weight status, gestational days smoked, pre-





Table 3. Analysis of covariance for 7 year blood pressure 
 
Average Systolic 




95% Confidence Interval 
P value
b 
Lower Bound Upper Bound 
7 Year Systolic Blood Pressure 
Placebo 102.2
a 
11.3 100.0 104.4 0.625 
DHA 101.4
a 
10.7 99.3 103.5 0.625 
7 Year Diastolic Blood Pressure 
Placebo 62.3
a 
7.8 60.8 63.9 0.431 
DHA 61.5
a 
7.4 60.1 62.9 0.431 
a
Means appearing in the model are adjusted for 7 year weight status, gestational days smoked, pre-pregnancy weight 
status, child race, and child sex. 
b






Figure 1. 7 year systolic blood pressure 
a
Means appearing in the model are adjusted for 7 year weight status, gestational days smoked, pre-pregnancy weight 











































Figure 2. 7 year diastolic blood pressure 
a
Means appearing in the model are adjusted for 7 year weight status, gestational days smoked, pre-pregnancy weight 
status, child race, and child sex. 
 
 
Analysis of covariance 
Table 4 shows the ANCOVA analysis for 8 year SBP and DBP. There is no significant 
difference between placebo and DHA group for 8 year SBP or DBP (P = 0.973 and P = 0.510, 
respectively). Figures 3 and 4 show the means for 8 year SBP and DBP for placebo and DHA 
groups.  The means are adjusted for 8 year weight status, gestational days smoked, pre-
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Table 4. Analysis of covariance for 8 year blood pressure 





95% Confidence Interval 
P value
b 
Lower Bound Upper Bound 
8 Year Systolic Blood Pressure 
Placebo 104.0
a 
9.9 102.0 106.0 0.973 
DHA 104.0
a 
10.0 101.9 106.0 0.973 
8 Year Diastolic Blood Pressure 
Placebo 63.6
a 
6.4 62.3 64.9 0.510 
DHA 63.0
a 
6.5 61.7 64.3 0.510 
a
Means appearing in the model are adjusted for 8 year weight status, gestational days smoked, pre-pregnancy weight 
status, child race, and child sex. 
b





Figure 3. 8 year diastolic blood pressure 
a
Means appearing in the model are adjusted for 8 year weight status, gestational days smoked, pre-pregnancy weight 










































Figure 4. 8 year diastolic blood pressure 
a
Means appearing in the model are adjusted for 8 year weight status, gestational days smoked, pre-pregnancy weight 




Table 4 shows the correlation for 7 and 8 year SBP and DBP. For 7 year SBP, 7 year 
weight status (P = <0.001) and gestational days smoked (P = <0.001) are positively associated 
with 7 year SBP. For 7 year DBP, 7 year weight status (P = 0.015) is positively associated with 7 
year DBP. For 8 year SBP, 8 year weight status (P = <0.001) and gestational days smoked (P = 
0.005) are positively associated with 8 year SBP. For 8 year DBP, none of the values are 
significant.  At both 7 and 8 years, child weight status was positively correlated with gestational 
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Table 4. Correlation table for 7 and 8 year blood pressure 





7 year weight status 0.494 <0.001 
Gestational Days Smoked 0.336 <0.001 




7 year weight status 0.224 0.015 
Gestational Days Smoked 0.085 0.365 




8 year weight status 0.501 <0.001 
Gestational Days Smoked 0.271 0.005 




8 year weight status 0.164 0.094 
Gestational Days Smoked 0.143 0.144 
Pre-pregnancy weight status -0.102 0.300 
a
P value <0.05 is significant; values in bold are significant 
b
n = 117 
c






Chapter 5: Discussion 
Does supplementing with 600 mg DHA compared to a placebo during pregnancy result in 
lower BP at 7 and 8 years of age? We did not find evidence to support it does. For the secondary 
research question, what are possible predictors of increased BP at 7and 8 years of age?, we find 
childhood weight status and gestational days smoked to be predictors of higher BP in 7 and 8 
year old children. 
 Maternal DHA assignment is not shown to be significant at 7 or 8 years of age for either 
SBP or DBP. These results do not support our hypothesis that DHA has a protective effect on 
childhood BP.  These results agree with previous studies conducted on LCPUFAs and BP (8-10, 
28). However, other studies have found the LCPUFAs can decrease BP (2, 7) or that LCPUFAs 
can increase BP (3-6, 27). The studies showing a decrease in BP with higher LCPUFA levels 
examined the children’s BPs at 6 years of age. Our previous study did show significantly lower 
BP at 4-6 years of age in overweight/obese children (14). This could suggest that as children 
become older the protective effect of early DHA exposure on childhood BP in overweight/obese 
children is overcome by the effect of continued overweight/obesity.   
It is clear from the study that an overweight/obese weight status at both 7 and 8 years of 
age leads to a much higher SBP. The effect on DBP, however, is smaller or absent.  Child weight 
status is shown to be significant at 7 years with SBP and DBP and at 8 years with SBP only. 
Children ≥85
th
 percentile had significantly higher SBP at 7 and 8 years of age and DBP at 7 
years.  Increased weight is a well-known risk factor for hypertension in adults, and this 
relationship is also seen in children (34-37).  
 Maternal pre-pregnancy weight status did not prove to be significant at 8 years of age 
with either SBP or DBP. A review by Ludwig-Walz et al. (38) reviewed 16 research articles 
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analyzing the relationship between maternal pre-pregnancy weight status and offspring’s BP. 
This systematic review concluded that the evidence was suggestive, but limited. Maternal pre-
pregnancy weight may be associated with offspring weight, which then causes high BP (38).  
The dispersal of overweight/obese mothers is unevenly distributed as about 57% of the 
mothers in the DHA assignment group are overweight/obese, and 40% of the mothers in the 
placebo group are overweight/obese. This uneven distribution is also seen in the children’s 
weight status at 7 and 8 years. At 7 years, about 20% of the children in the placebo group and 
31% of the children in the DHA group are ≥85
th 
percentile and at 8 years, about 22% of the 
children in the placebo group and 29% of the children in the DHA group are ≥85
th 
percentile. 
This puts the children in the DHA group at somewhat of a disadvantage as obesity is related to 
higher BP.  
 Several studies have found a positive association between maternal smoking and 
childhood BP (39-42). Li et al. (43) found that maternal smoking was associated with childhood 
obesity which could lead to increased BP, but smoking itself was not associated with higher BP. 
Bergel et al. (44) did not find an association between smoking and childhood BP either. We find 
a positive relationship with 7 and 8 year SBP and gestational days smoked. We also find a 
positive correlation between gestational days smoked and childhood weight status at 7 and 8 
years (P = 0.004 and P = 0.002, respectively; results not shown).  More research is needed in this 
area to confirm the association between maternal smoking and childhood BP.   
Other Research/Future Research 
  Childhood BP is a common area of study as hypertension is becoming more prevalent. A 
study by Lindberg et al. (45) supplemented children from 6 weeks to 6 months of age with iron 
or a placebo. The study found that the low birth weight children supplemented with iron had a 
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protective effect resulting in lower BP at 7 years of age. This and research like it open the door 
for other studies examining vitamins, minerals, or fatty acids to see what potential relationship 
they may have with childhood BP. More studies are needed to find other possible contributors to 
increased BP. 
Implications of Findings 
 While DHA supplementation does not prove to be significant at 7 or 8 years of age, the 
findings that child weight status and gestational days smoked impact childhood BP gives us 
further reason to improve the rising obesity rates in the country. Other research, like the 
Lindberg et al. (45) study give us further reason to keep investigating different nutritional factors 
that could improve BP. 
The main limitation of this study is that BP is not the primary outcome of the original 
study. Therefore, the methods used to measure BP may not be the most optimal. While the 
children were sitting and lying down prior to the measurements, some of the children were active 
between tasks or talking during the measurements, which could result in inaccurate readings. 
Although the children were instructed to remain still and quiet during the measurements, the 
children were not always compliant.  
Possible limitations from the original cohort include that some prenatal vitamins that 
contain DHA were introduced to the market during the time of enrollment. Women who 
consumed less than 300 mg DHA from other sources were not excluded from this study. Twenty 
seven percent of the participants from the original cohort took additional DHA. Dietary DHA 
intake was not recorded from the mothers, but the blood analysis is a sensitive measure to DHA 





While DHA supplementation did not prove to have an effect on childhood BP at 7 and 8 
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